# Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

> **NCT01118026** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 101 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** ABVD
- **DRUG:** BEACOPP
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT01118026
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-09-29
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2021-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118026, "Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01118026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*